GlassScriptPhysician profile
Kasey Lee Johnson
NPI 1417609603
$4,980.66
in general payments reported to CMS, 2019-2025
35 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,408 · 2023: $1,386 · 2024: $1,106 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,572.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $837.97 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $785.67 | 2022-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $396.96 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $387.16 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $350.02 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $287.51 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $283.51 | 2022-2025 | |
| Pfizer INC. | $246.43 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $190.94 | 2022-2024 | Camzyos, Eliquis |
| Dexcom, INC. | $152.98 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $123.86 | 2022 | |
| Sanofi-Aventis U.S. LLC | $83.40 | 2022-2023 | |
| Astellas Pharma US INC | $81.39 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $80.74 | 2023-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.06 | 2022-2024 | Trulance, Xifaxan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $56.24 | 2023 | Verquvo, Belsomra, Steglatro |
| Daiichi Sankyo INC. | $51.87 | 2022-2023 | Injectafer |
| Esperion Therapeutics, INC. | $50.50 | 2022-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $48.11 | 2024 | Rexulti |
| Ardelyx, INC. | $40.55 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $38.99 | 2022-2023 | Trintellix |
| Eisai INC. | $38.04 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.65 | 2023 | |
| Phathom Pharmaceuticals, INC. | $37.29 | 2024 | Voquezna |
| Mylan Specialty L.P. | $35.56 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.40 | 2022-2023 | Jardiance |
| Scilex Pharmaceuticals INC. | $24.44 | 2023 | Ztlido |
| Lundbeck LLC | $23.77 | 2023 | Rexulti |
| Sumitomo Pharma America, INC. | $23.48 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $18.22 | 2024 | Inspire |
| Inari Medical, INC. | $15.44 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Exact Sciences Corporation | $14.79 | 2023 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $14.63 | 2022 | |
| Genentech USA, INC. | $13.48 | 2023 | Xolair |
| Sunovion Pharmaceuticals INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kasey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.